Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities

References

• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70:1119–1133. doi:10.1002/hep.30702
   PubMed Web of Science ®Google Scholar
• Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017–1025. doi:10.1016/j.metabol.2016.01.012
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals. J Clin Endocrinol Metab. 2022;107:2691–2700. doi:10.1210/clinem/dgac321
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377–386. doi:10.1038/s41575-019-0144-8
   PubMed Web of Science ®Google Scholar
• Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021;S1542-3565:1276.
   Google Scholar
• Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;S1542-3565:01280–01285.
   Google Scholar
• Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75:1284–1291. doi:10.1016/j.jhep.2021.07.035
   PubMed Web of Science ®Google Scholar
• van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology. 2022. doi:10.1002/hep.32642
   Web of Science ®Google Scholar
• Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18:1649. doi:10.3390/ijms18081649
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65:1062–1079. doi:10.1016/j.metabol.2015.11.006
   PubMed Web of Science ®Google Scholar
• White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210–9213. doi:10.1016/S0021-9258(19)50409-4
   PubMed Web of Science ®Google Scholar
• Cook KS, Min HY, Johnson D, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science. 1987;237:402–405. doi:10.1126/science.3299705
   PubMed Web of Science ®Google Scholar
• Lo JC, Ljubicic S, Leibiger B, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158:41–53. doi:10.1016/j.cell.2014.06.005
   PubMed Web of Science ®Google Scholar
• Baldo A, Sniderman AD, St-Luce S, et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest. 1993;92:1543–1547. doi:10.1172/JCI116733
   PubMed Web of Science ®Google Scholar
• Cianflone K, Roncari DAK, Maslowska M, et al. Adipsin / Acylation Stimulating Protein System in Human Adipocytes: regulation of Triacylglycerol Synthesis. Biochemistry. 1994;33:9489–9495. doi:10.1021/bi00198a014
   PubMed Web of Science ®Google Scholar
• Qiu Y, Wang SF, Yu C, et al. Association of circulating adipsin, visfatin, and adiponectin with nonalcoholic fatty liver disease in adults: a case-control study. Ann Nutr Metab. 2019;74:44–52. doi:10.1159/000495215
   PubMed Web of Science ®Google Scholar
• Gu Y, Luo J, Chen Q, et al. Inverse association of serum adipsin with the remission of nonalcoholic fatty-liver disease: a 3-year community-based cohort study. Ann Nutr Metab. 2022;78:21–32. doi:10.1159/000520368
   PubMed Web of Science ®Google Scholar
• Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575–1581. doi:10.1249/MSS.0b013e31821ece12
   PubMed Web of Science ®Google Scholar
• Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol. 2000;35(5):319–324. doi:10.1097/00004424-200005000-00006
   PubMed Web of Science ®Google Scholar
• Chen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076. doi:10.1038/srep19076
   PubMed Web of Science ®Google Scholar
• Punthakee Z, Goldenberg R, Katz P; Diabetes Canada Clinical Practice Guidelines Expert Committee. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42(Suppl 1):S10–S15. doi:10.1016/j.jcjd.2017.10.003
   PubMedGoogle Scholar
• Zhu JR, Gao RL, Zhao SP, et al. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15:1–29.
   PubMedGoogle Scholar
• Jia J, Liu R, Wei W, et al. Monocyte to high-density lipoprotein cholesterol ratio at the nexus of type 2 diabetes mellitus patients with metabolic-associated fatty liver disease. Front Physiol. 2021;12:762242. doi:10.3389/fphys.2021.762242
   PubMed Web of Science ®Google Scholar
• Li N, Xie G, Zhou B, et al. Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease. Front Physiol. 2021;12:696163. doi:10.3389/fphys.2021.696163
   PubMed Web of Science ®Google Scholar
• Zhu C, Ma H, Huang D, et al. J-shaped relationship between serum prolactin and metabolic-associated fatty liver disease in female patients with type 2 diabetes. Front Endocrinol. 2022;13:815995. doi:10.3389/fendo.2022.815995
   PubMed Web of Science ®Google Scholar
• Huh JH, Kim KJ, Kim SU, Cha BS, Lee BW. Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. Hepatobiliary Pancreat Dis Int. 2022;21:241–247. doi:10.1016/j.hbpd.2022.03.009
   PubMed Web of Science ®Google Scholar
• Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153–159. doi:10.1016/j.jhep.2010.05.037
   PubMed Web of Science ®Google Scholar
• Rana R, Shearer AM, Fletcher EK, et al. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab. 2019;29:99–113. doi:10.1016/j.molmet.2019.08.019
   PubMed Web of Science ®Google Scholar
• Torres Do Rego A, Perez de Isla L, Saltijeral Cerezo A, et al. Cholesterol control according to the presence of metabolic syndrome in coronary and diabetic patients. Relationship with non-alcoholic fatty liver disease. Eur J Intern Med. 2014;25:438–443. doi:10.1016/j.ejim.2014.03.014
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng X, Xie X, et al. Body fat distribution and circulating adipsin are related to metabolic risks in adult patients with newly diagnosed growth hormone deficiency and improve after treatment. Biomed Pharmacother. 2020;132:110875. doi:10.1016/j.biopha.2020.110875
   PubMed Web of Science ®Google Scholar
• Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma adipsin as a biomarker and its implication in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:1855–1861. doi:10.2147/DMSO.S253967
   PubMedGoogle Scholar
• Guo D, Liu J, Zhang P, et al. Adiposity measurements and metabolic syndrome are linked through circulating neuregulin 4 and adipsin levels in obese adults. Front Physiol. 2021;12:667330. doi:10.3389/fphys.2021.667330
   PubMed Web of Science ®Google Scholar
• Schrover IM, van der Graaf Y, Spiering W, Visseren FL. The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. Eur J Prev Cardiol. 2018;25:1548–1557. doi:10.1177/2047487318790722
   PubMed Web of Science ®Google Scholar
• Chedraui P, Pérez-López FR, Escobar GS, et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas. 2014;79:86–90. doi:10.1016/j.maturitas.2014.06.008
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng X, Xie X, et al. Correlation of increased serum adipsin with increased cardiovascular risks in adult patients with growth hormone deficiency. Endocr Pract. 2019;25:446–453. doi:10.4158/EP-2018-0541
   PubMed Web of Science ®Google Scholar
• El Sehmawy AA, Diab FEA, Hassan DA, et al. Utility of adipokines and IL-10 in association with anthropometry in prediction of insulin resistance in obese children. Diabetes Metab Syndr Obes. 2022;15:3231–3241. doi:10.2147/DMSO.S377072
   PubMed Web of Science ®Google Scholar
• Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405–408. doi:10.1126/science.3299706
   PubMed Web of Science ®Google Scholar
• Derosa G, Fogari E, D’Angelo A, et al. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 2013;36:914–920. doi:10.1007/s10753-013-9620-4
   PubMed Web of Science ®Google Scholar
• Azizi M, Tadibi V, Behpour N. The effect of aerobic exercise training on β-cell function and circulating levels of adipsin in community of obese women with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2016;37:298–304. doi:10.1007/s13410-016-0504-7
   Web of Science ®Google Scholar
• Pomeroy C, Mitchell J, Eckert E, et al. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol. 1997;108(3):507–515. doi:10.1046/j.1365-2249.1997.3921287.x
   PubMed Web of Science ®Google Scholar
• Milek M, Moulla Y, Kern M, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. 2022;23:2222. doi:10.3390/ijms23042222
   PubMed Web of Science ®Google Scholar
• Zhou Q, Ge Q, Ding Y, et al. Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Investig. 2018;9:1128–1134. doi:10.1111/jdi.12819
   PubMed Web of Science ®Google Scholar
• Platt KA, Claffey KP, Wilkison WO, Spiegelman BM, Ross SR. Independent regulation of adipose tissue-specificity and obesity response of the adipsin promoter in transgenic mice. J Biol Chem. 1994;269:28558–28562. doi:10.1016/S0021-9258(19)61941-1
   PubMed Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40:2082–2089. doi:10.1111/liv.14548
   PubMed Web of Science ®Google Scholar
• Zhou XD, Cai J, Targher G, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21:270. doi:10.1186/s12933-022-01697-0
   PubMed Web of Science ®Google Scholar